Clinical trial
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00022282 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00022282 |
|---|---|
| Title | AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | shark cartilage extract AE-941 |
| Start date | Apr 1, 2001 |
| Primary completion | Mar 1, 2007 |
| First posted | Oct 15, 2003 |
| Last update posted | Feb 28, 2013 |
| Countries | Canada |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: